Breadcrumbs

Lymphoma - haematology

Lymphoma

Non-Hodgkin lymphoma

Hodgkin lymphoma

Burkitt lymphoma

Mantle cell lymphoma

Primary central nervous system (CNS) lymphoma

Waldenstrom macroglobulinaemia

Lymphoma

Protocol Administration at chemotherapy unit level Review date
Lymphoma brentuximab vedotin High September 2022
Lymphoma GDP (gemcitabine dexamethasone cISplatin) Medium September 2022
Lymphoma gemcitabine and vinORELBine Medium March 2020
Lymphoma DHAP (dexamethasone cytarabine cISplatin) High March 2022

Non-Hodgkin lymphoma

Protocol Administration at chemotherapy unit level Review date
Cutaneous T-cell lymphoma vorinostat
Low September 2021
Non-Hodgkin lymphoma bendamustine and obinutuzumab
Medium September 2020
Non-Hodgkin lymphoma RITUximab Medium September 2021
Non-Hodgkin lymphoma RITUximab Maintenance Low-medium September 2021
Non-Hodgkin lymphoma bendamustine and RITUximab
Medium September 2022
Non-Hodgkin lymphoma chlorambucil and RITUximab Medium September 2021
Non-Hodgkin lymphoma hyper CVAD part A High September 2020
Non-Hodgkin lymphoma hyper CVAD Part B High September 2020
NK T-Cell lymphoma SMILE (dexamethasone methotrexate IFOSFamide asparaginase etoposide) High September 2020
Non-Hodgkin lymphoma ICE (fractionated IFOSFamide cARBOplatin etoposide) High September 2020
Non-Hodgkin lymphoma idelalisib
Low September 2021
Non-Hodgkin lymphoma obinutuzumab maintenance
Low September 2022
Non-Hodgkin lymphoma O-CHOP21 (obinutuzumab CYCLOPHOSPHamide DOXOrubicin vinCRISTine prednisolone)
Medium September 2022
Non-Hodgkin lymphoma O-CVP (obinutuzumab CYCLOPHOSPHamide vinCRISTine prednisolone)
Medium September 2022
Non-Hodgkin lymphoma RICE (RITUximab infusional IFOSFamide cARBOplatin etoposide) High September 2020
Non-Hodgkin lymphoma R-DHAP (RITUximab dexamethasone cytarabine cISplatin) High September 2020
Non-Hodgkin lymphoma R-GemOX (RITUximab gemcitabine oxaliplatin) Medium September 2020
Non-Hodgkin lymphoma R-DHAOx (RITUximab dexamethasone cytarabine oxaliplatin) High September 2022
Non-Hodgkin Lymphoma R-CVP (RITUximab CYCLOPHOSPHamide vincristine Prednisolone) Medium September 2020
Non-Hodgkin lymphoma bendamustine and RITUximab Medium September 2020
Peripheral T-cell lymphoma pralatrexate
Medium June 2022
Peripheral T-cell lymphoma romidepsin
Medium June 2022
Non-Hodgkin lymphoma R-MiniCHOP (RITUximab CYCLOPHOSPHamide DOXOrubicin vinCRISTine prednisolone) High March 2021
Non-Hodgkin lymphoma DHAC (dexamethasone cytarabine cARBOplatin) High March 2021
Non-Hodgkin lymphoma CHOEP21 (CYCLOPHOSPHamide DOXOrubicin vinCRISTine etoposide prednisolone) High March 2021
Non-Hodgkin lymphoma CHOEP14 (CYCLOPHOSPHamide DOXOrubicin vinCRISTine etoposide prednisolone) High September 2022
Non-Hodgkin Lymphoma CHOP14 (CYCLOPHOSPHamide DOXOrubicin vincristine Prednisolone) Medium-high September 2022
Non-Hodgkin Lymphoma CHOP21 (CYCLOPHOSPHamide DOXOrubicin vincristine Prednisolone) Medium March 2021
Non-Hodgkin lymphoma R-CHOP21 (RITUximab CYCLOPHOSPHamide DOXOrubicin vinCRISTine Prednisolone) Medium March 2021
Non-Hodgkin Lymphoma R-CHOP14 (RITUximab CYCLOPHOSPHamide DOXOrubicin vinCRISTine Prednisolone) Medium-high September 2022
Non-Hodgkin lymphoma DA-R-EPOCH (dose adjusted RITUximab etoposide prednisolone vinCRISTine CYCLOPHOSPHamide DOXOrubicin) High September 2021
Non-Hodgkin lymphoma R-CHOEP14 (RITUximab CYCLOPHOSPHamide DOXOrubicin vinCRISTine etoposide prednisolone) High March 2021

Hodgkin lymphoma

Protocol Administration at chemotherapy unit level Review date
Hodgkin lymphoma ABVD (DOXOrubicin bleomycin vinBLASTine dacarbazine) early stage Medium-high September 2021
Hodgkin lymphoma ABVD (DOXOrubicin bleomycin vinBLASTine dacarbazine) advanced stage Medium-high September 2021
Hodgkin lymphoma BEACOPP escalated dose (bleomycin etoposide DOXOrubicin CYCLOPHOSPHamide vinCRISTine procarbazine prednisolone) High September 2021
Hodgkin lymphoma ChlVPP (chlorambucil vinBLASTine procarbazine prednisolone) High September 2022
Hodgkin lymphoma ICE (fractionated IFOSFamide cARBOplatin etoposide) High September 2022
Hodgkin lymphoma ICE (infusional IFOSFamide cARBOplatin etoposide) High September 2022
Hodgkin lymphoma pembrolizumab
Low September 2021

Burkitt lymphoma

Protocol Administration at chemotherapy unit level Review date
Burkitt lymphoma dose modified CODOX-M (CYCLOPHOSPHamide vinCRISTine DOXOrubicin methotrexate) High March 2020
Burkitt lymphoma IVAC (IFOSFamide etoposide cytarabine) High March 2020

Mantle cell lymphoma

Protocol Administration at chemotherapy unit level Review date
Mantle cell lymphoma ibrutinib Low March 2022
Mantle cell lymphoma R-CHOP (RITUximab CYCLOPHOSPHamide DOXOrubicin vinCRISTine prednisolone) Medium-high September 2020
Mantle cell lymphoma R-DHAP (RITUximab dexamethasone cytarabine cISplatin) High September 2020
Mantle cell lymphoma R-maxi-CHOP (RITUximab CYCLOPHOSPHamide DOXOrubicin vinCRISTine prednisolone) High September 2021
Mantle cell lymphoma R-HiDAC (RITUximab and cytarabine) High September 2021

Primary CNS lymphoma

Protocol Administration at chemotherapy unit level Review date
Primary CNS lymphoma (PCNSL) R-MPV/high dose cytarabine treatment overview High March 2021
Primary CNS lymphoma (PCNSL) R-MPV (RITUximab methotrexate procarbazine vinCRISTine ) - part 1 High March 2021
Primary CNS lymphoma (PCNSL) consolidation high dose cytarabine - part 2 High March 2021

Waldenstrom macroglobulinaemia

Protocol Administration at chemotherapy unit level Review date
Waldenstrom macroglobulinaemia DRC (dexamethasone RITUximab CYCLOPHOSPHamide) Medium March 2021

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Local radiotherapy services required
  4. Non-formulary drug included in the protocol
  5. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.

^ Back to top